NEWS
MEDIA
COVID-19 PODCAST
Australia's Vaccine Agreements
-
Pre
Clinical -
Clinical
Phase I -
Clinical
Phase II -
Clinical
Phase III -
Post-Licensure Surveillance
Phase IV
In 2020, the Australian Government entered into four Advanced Purchase Agreements (APA) for the supply of COVID-19 vaccines, if they prove safe and effective. More than $3.3 billion has been invested through these agreements, putting Australia in a strong position to access safe and effective vaccines when they become available.
In 2021, three of these vaccines are still active, with the 4th (University of Queensland) withdrawn from clinical trials. Details of the three vaccines with Australian APAs are detailed below, noting that the Pfizer/BioNTech and University of Oxford/AstraZeneca COVID-19 vaccines have been granted provisional registration from the TGA, and the Novavax COVID-19 vaccine is still in phase III clinical trials.
University of Oxford | AstraZeneca COVID-19 vaccine
Pfizer | BioNTech COVID-19 vaccine
Novavax COVID-19 vaccine
COVAX Facility
The COVAX Facility is a global initiative designed to support rapid, fair and equitable access to COVID-19 vaccines. It allows all participating countries, regardless of income levels, to have equal access to a portfolio of vaccines once they have been developed. COVAX is coordinated by Gavi with help from member countries, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization, and UNICEF.
